Page last updated: 2024-12-07
3,3'-neotrehalosadiamine
Description
3,3'-neotrehalosadiamine: from bacterial strain K169-B91; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3,3'-neotrehalosadiamine : An amino disaccharide consisting of alpha- and beta-D-kanosaminyl residues joined by a (1<->1)-linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 128505 |
| CHEBI ID | 75319 |
| SCHEMBL ID | 17866969 |
| MeSH ID | M0142954 |
Synonyms (16)
| Synonym |
|---|
| 3,3'-neotrehalosadiamine |
| bmy 28251 |
| 3-amino-3-deoxy-beta-d-glucopyranosyl 3-amino-3-deoxy-alpha-d-glucopyranoside |
| alpha-d-glucopyranoside, 3-amino-3-deoxy-beta-d-glucopyranosyl 3-amino-3-deoxy- |
| 3,3'-diamino-3,3'-dideoxy-alpha,beta-trehalose |
| bu-2797 |
| beta-d-glc3n-(1<->1)-alpha-d-gl3n |
| CHEBI:75319 |
| beta-d-kanosaminyl-(1<->1)-alpha-d-kanosamine |
| bmy-28251 |
| bu 2797 |
| 104196-14-7 |
| DTXSID80146339 |
| SCHEMBL17866969 |
| Q27145213 |
| (2r,3r,4s,5s,6r)-4-amino-2-[(2s,3r,4s,5s,6r)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-3,5-diol |
Roles (2)
| Role | Description |
|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
| Class | Description |
|---|
| glycosyl glycoside derivative | A disaccharide derivative that is formally obtained from a glycosyl glycoside. |
| amino disaccharide | A disaccharide derivative that is a disaccharide having one or more substituted or unsubstituted amino groups in place of hydroxy groups at unspecified positions. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 11.96 (24.57) | | Research Supply Index | 2.20 (2.92) | | Research Growth Index | 4.16 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |